Micron Says The Best Is Yet To Come After Record Q1

Micron reported fiscal Q1 revenue of $13.64 billion and adjusted EPS of $4.78, with sales up 20.5% YoY, operating cash flow of $8.41 billion and adjusted free cash flow of $3.9 billion, and ended the quarter with ~$12 billion in cash and equivalents. The board approved an $0.115 quarterly dividend and management issued a very strong fiscal Q2 outlook—revenue of $18.7 billion ± $400 million and adjusted EPS of $8.42 ± $0.20—while forecasting ~15.5% tax rate, raising fiscal 2026 capex to ~$20 billion and detailing multi-year fab buildouts (Idaho first wafers in early 2027, New York fab construction in 2026). The beat and robust guidance prompted broad analyst upgrades and large price-target increases and sent the stock up ~14.5% premarket to $258.17, trading near its 52-week high.

Analysis

Market structure: Micron (MU) is a direct beneficiary of a persistent DRAM/NAND supply shortfall and accelerating HBM adoption (Mgmt: HBM market ~40% CAGR to 2028). Winners: MU, semi-equipment names (LRCX, AMAT, ASML suppliers), and GPU/HPC OEMs (NVDA) that capture HBM value; losers: memory-heavy original equipment manufacturers facing higher BOMs and any smaller memory peers unable to fund capex. The guidance ($18.7B Q2 revenue ±$0.4B; FY26 capex ~$20B) signals sustained pricing power and margin expansion into FY26–FY28 as industry supply lags demand.

Risk assessment: Tail risks include a sudden AI-led demand slowdown (20%+ DRAM demand reversion), accelerated competitor capacity additions creating oversupply, geopolitically driven export controls to China, or execution delays at Idaho/NY fabs (first Idaho wafers early 2027). Immediate (days) risk is sentiment reversal post-earnings; short-term (weeks–months) hinges on monthly spot DRAM/NAND prices and NVDA/AI OEM demand; long-term (2027–2030) depends on capex execution, yields, and unit economics. Hidden dependency: MU’s strong outlook assumes stable OEM procurement and no punitive tariffs or missed equipment deliveries.

Trade implications: Tactical long exposure to MU is warranted to capture upgrade momentum and FCF-driven buybacks/dividend optionality, while also buying semi-equipment (LRCX, AMAT) to play capex. Use defined-risk option structures (debit call spreads or protective puts) around key catalysts: NVDA earnings, monthly DRAM price reports, and next fiscal quarters. Rotate modestly into semiconductors and equipment and trim rate-sensitive/consumer cyclicals if memory-driven input costs compress margins there.

Contrarian angles: The street’s upgrades may underprice execution and capex risk—$20B capex raises breakeven and could meaningfully depress ROIC if HBM adoption stalls. The 14% one-day move likely overstates near-term visibility; historical memory cycles (2016–18) show fast upside followed by sharp corrections when capacity inflects. Unintended consequence: aggressive fab builds by MU could trigger competitors to accelerate capacity or pricing responses, producing a multi-year supply swing that compresses margins by 2028–2030.

Key Decisions for Investors

• Establish a 3% portfolio long position in MU around current levels (~$255–$265). Target 12-month price $350 (≈+35%), set a hard stop-loss at -18% (~$210) and scale out at +25% and +50% performance points.
• Buy a defined-risk long-call spread: MU Jan 2027 300/450 call spread sized to 1.5% portfolio risk (max premium = position size). Rationale: levered exposure to FY26–FY28 HBM/DRAM tailwinds while capping downside premium.
• Allocate 1% each to LRCX and AMAT (total 2%) to play the $20B capex tailwind. Target 9–18 month returns of 25–40% if semi capex stays elevated; trim if weekly/semi-monthly order flow (book-to-bill) drops below 0.9.
• Buy short-dated downside protection: MU 3-month puts ~20% OTM (strike ≈$205) sized to cover 1% portfolio exposure within 10 trading days to hedge against a >15% drawdown from inventory or regulatory shocks.
• Initiate relative-value pair only after confirmation of sustained price momentum: go long MU and short SSNLF (Samsung ADR) on a 1:1 notional basis if DRAM spot prices rise >10% month-over-month for two consecutive months—this trades company-specific execution vs. cyclical exposure.